- The human body has distinct microbiomes in several areas, including the breast.
- Most breast cancer tumors are estrogen receptor-positive (ER+), changing the breast microbiome to encourage cancer growth.
- Studies show that endocrine-targeted therapy and diet can modify the breast microbiome to reduce breast cancer growth and prevent recurrences.
- Researchers at Wake Forest University in North Carolina found that probiotics may enhance the anticancer activity of tamoxifen and other endocrine-targeted medications.
Next to skin cancer,
Two-thirds of breast cancer tumors are
Scientists at Wake Forest University in Winston-Salem, NC, recently discovered that probiotics might amplify the anticancer effect of breast cancer drug tamoxifen, a common endocrine-targeted therapy.
Lead researcher Katherine L. Cook, Ph.D., presented the team’s findings at the Endocrine Society’s annual conference ENDO 2022 in June. Dr. Cook is an associate professor in the Department of Surgery and Cancer Biology at Wake Forest University School of Medicine.
Medical News Today discussed this research with Dr. Parvin Peddi, medical oncologist and director of Breast Medical Oncology for the Margie Petersen Breast Center at Providence Saint John’s Health Center and Associate Professor of Medical Oncology at Saint John’s Cancer Institute in Santa Monica, California. She was not involved in the study.
Dr. Peddi explained: “Normal breast tissue responds to the fluctuating hormones in a woman’s body, as every woman knows with periods and menstrual cycles or if someone has been pregnant. […When] there are changes in the hormone level, breast tissue has so-called receptors for estrogen inside the cells, and they’re basically these keyholes.”
Dr. Peddi said most breast cancer tumors trigger this mechanism to create more estrogen receptors and grow.
A microbiome is a collection of microorganisms (such as bacteria, viruses, and fungi) that inhabit a particular environment. Distinct microbiomes exist in and within the human body.
While the gut microbiome is the largest and most well-known, the breast also has its own microbiome.
Dr. Cook was involved in earlier research demonstrating the Mediterranean diet’s potential to reduce breast cancer risk by changing the breast microbiome. She and fellow Wake Forest researchers wondered if endocrine-targeted therapies used to prevent ER+ breast cancer recurrence might show a similar effect.
Endocrine-targeted therapy, also called hormone therapy, is prescribed to help reduce estrogen levels or block its effects. Tamoxifen is a drug commonly used to reduce the risk of breast cancer in high-risk individuals and help prevent recurrence after surgical removal. Other examples include fulvestrant and aromatase inhibitors, such as exemestane.
Dr. Peddi also explained that endocrine therapy is generally well-tolerated with mild side effects: “[Endocrine therapy is] not like chemo that you go with a big hammer and try to kill cancer that way. [It’s] a slow taking away of the estrogen, [a] slow dying option with cancer cells.”
Dr. Cook and her Wake Forest team conducted three sub-studies to investigate how breast cancer drug tamoxifen and other endocrine-targeted therapies affect the breast microbiome in fighting ER+ tumors.
Lactobacillus’ anticancer potential
During the first preclinical part of the study, a mouse model was fed a Mediterranean-like or a Western, high fat diet and given tamoxifen for three months.
They found that the animals given tamoxifen had elevated levels of Lactobacillus in their breast tissue. Lactobacillus is a Gram-positive bacteria known for probiotic anti-inflammatory properties.
Next, the researchers injected Lactobacillus into the mammary glands of mice engineered to develop breast tumors. These animals showed decreased breast tumor formation and proliferation.
Larger animal study
The second phase of this study involved larger animals. Their ovaries had been removed to simulate menopause.
These subjects were given tamoxifen for 2.5 years. These animals also had elevated levels of Lactobacillus in their breast tissue.
Human breast tissue examined
In the study’s third phase, Dr. Cook and her colleagues analyzed tissue from ER+ breast tumors from women receiving
Samples from women with elevated levels of Gram-positive bacteria in their tumors showed lower levels of cancer cell growth.
Dr. Cook concluded:
“The fact that we have identified this potential population in the breast tissue that’s regulated by most cancer therapies and that this population does have potential anticancer signaling [indicates] a conclusion that the breast has its own unique bacterial microbiome that can be modified by diet and drug administration and that it could represent a novel targetable factor to prevent breast cancer risk and reoccurrence.”
As a preclinical study, this work is subject to some limitations.
Dr. Cook acknowledged the need to “see whether or not [the findings] could be applicable in clinical studies.”
Also, as Dr. Peddi noted, the study does not prove causality.
Dr. Cook mentioned that her team is currently looking at using over-the-counter probiotics combined with endocrine-targeted medications to improve outcomes.
This research phase only looked at Lactobacillus’ effect on the breast microbiome. Dr. Cook said her team is exploring whether all probiotics can alter the breast microbiome.